UBS lowered the firm’s price target on Trinity Capital (TRIN) to $17 from $18 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIN:
- Candel Therapeutics enters into $130M term loan facility
- Trinity Capital provides $130M in growth capital to Candel Therapeutics
- Trinity Capital Announces Q3 2025 Portfolio Activity
- Trinity Capital originates $773M of new commitments in Q3
- Trinity Capital provides $45M in growth capital to Rapid Micro Biosystems